Scientists Find a Potential Cure for Chronic Hepatitis B - The New York Times
1 min read
The story
GSK's bepirovirsen achieved a functional cure in ~20% of chronic hepatitis B patients in late-stage Phase III trials, a historically unprecedented result for a disease with ~300 million sufferers globally. The data creates a meaningful re-rating catalyst for GSK, with a partnered royalty upside for Ionis Pharmaceuticals, though the consensus is already mixed and the stock barely moved on the news.
The case — both sides
The house read
Long IONS over GSK on bepirovirsen data — Ionis holds royalty rights and is smaller-cap, meaning the same drug has more leverage on the equity than on GSK's diversified book.
Wrong ifFDA/EMA regulatory path is unclear — 'functional cure' in 20% may not satisfy a label claim sufficient to displace entecavir/tenofovir standards of care, which are cheap generics; any signal of a narrow label or subgroup limitations collapses the pair. Also, IONS carries its own pipeline credit risk unrelated to this program.
Published read · research, not advice